358 related articles for article (PubMed ID: 31713863)
1. A randomised controlled trial of extended anticoagulation treatment versus standard treatment for the prevention of recurrent venous thromboembolism (VTE) and post-thrombotic syndrome in patients being treated for a first episode of unprovoked VTE (the ExACT study).
Bradbury C; Fletcher K; Sun Y; Heneghan C; Gardiner C; Roalfe A; Hardy P; McCahon D; Heritage G; Shackleford H; Hobbs FR; Fitzmaurice D
Br J Haematol; 2020 Mar; 188(6):962-975. PubMed ID: 31713863
[TBL] [Abstract][Full Text] [Related]
2. Trial Protocol: a randomised controlled trial of extended anticoagulation treatment versus routine anticoagulation treatment for the prevention of recurrent VTE and post thrombotic syndrome in patients being treated for a first episode of unprovoked VTE (The ExACT Study).
Tullett J; Murray E; Nichols L; Holder R; Lester W; Rose P; Hobbs FD; Fitzmaurice D
BMC Cardiovasc Disord; 2013 Mar; 13():16. PubMed ID: 23497371
[TBL] [Abstract][Full Text] [Related]
3. Patient-level meta-analysis: effect of measurement timing, threshold, and patient age on ability of D-dimer testing to assess recurrence risk after unprovoked venous thromboembolism.
Douketis J; Tosetto A; Marcucci M; Baglin T; Cushman M; Eichinger S; Palareti G; Poli D; Tait RC; Iorio A
Ann Intern Med; 2010 Oct; 153(8):523-31. PubMed ID: 20956709
[TBL] [Abstract][Full Text] [Related]
4. Long-term risk of recurrence in patients with a first unprovoked venous thromboembolism managed according to d-dimer results; A cohort study.
Kearon C; Parpia S; Spencer FA; Schulman S; Stevens SM; Shah V; Bauer KA; Douketis JD; Lentz SR; Kessler CM; Connors JM; Ginsberg JS; Spadafora L; Julian JA
J Thromb Haemost; 2019 Jul; 17(7):1144-1152. PubMed ID: 31033194
[TBL] [Abstract][Full Text] [Related]
5. Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis.
Khan F; Rahman A; Carrier M; Kearon C; Weitz JI; Schulman S; Couturaud F; Eichinger S; Kyrle PA; Becattini C; Agnelli G; Brighton TA; Lensing AWA; Prins MH; Sabri E; Hutton B; Pinede L; Cushman M; Palareti G; Wells GA; Prandoni P; Büller HR; Rodger MA;
BMJ; 2019 Jul; 366():l4363. PubMed ID: 31340984
[TBL] [Abstract][Full Text] [Related]
6. CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients.
Lee AY; Bauersachs R; Janas MS; Jarner MF; Kamphuisen PW; Meyer G; Khorana AA;
BMC Cancer; 2013 Jun; 13():284. PubMed ID: 23764005
[TBL] [Abstract][Full Text] [Related]
7. Extended Anticoagulant and Aspirin Treatment for the Secondary Prevention of Thromboembolic Disease: A Systematic Review and Meta-Analysis.
Marik PE; Cavallazzi R
PLoS One; 2015; 10(11):e0143252. PubMed ID: 26587983
[TBL] [Abstract][Full Text] [Related]
8. Residual vein thrombosis and serial D-dimer for the long-term management of patients with deep venous thrombosis.
Prandoni P; Vedovetto V; Ciammaichella M; Bucherini E; Corradini S; Enea I; Cosmi B; Mumoli N; Visonà A; Barillari G; Bova C; Quintavalla R; Zanatta N; Pedrini S; Villalta S; Camporese G; Testa S; Parisi R; Becattini C; Cuppini S; Pengo V; Palareti G;
Thromb Res; 2017 Jun; 154():35-41. PubMed ID: 28407492
[TBL] [Abstract][Full Text] [Related]
9. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study.
Raskob G; Ageno W; Cohen AT; Brekelmans MP; Grosso MA; Segers A; Meyer G; Verhamme P; Wells PS; Lin M; Winters SM; Weitz JI; Büller HR
Lancet Haematol; 2016 May; 3(5):e228-36. PubMed ID: 27132697
[TBL] [Abstract][Full Text] [Related]
10. D-dimer and reduced-dose apixaban for extended treatment after unprovoked venous thromboembolism: the Apidulcis study.
Palareti G; Poli D; Ageno W; Legnani C; Antonucci E; Bucherini E; Testa S; Paoletti O; Chistolini A; Serrao A; Martinelli I; Bucciarelli P; Falanga A; Tosetto A; Sarti L; Mastroiacovo D; Cosmi B; Visonà A; Santoro RC; Zanatta N; Grandone E; Bertù L; Pengo V; Caiano L; Prandoni P
Blood Adv; 2022 Dec; 6(23):6005-6015. PubMed ID: 35914222
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study.
Larsen TB; Skjøth F; Kjældgaard JN; Lip GYH; Nielsen PB; Søgaard M
Lancet Haematol; 2017 May; 4(5):e237-e244. PubMed ID: 28411120
[TBL] [Abstract][Full Text] [Related]
12. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.
Lee AYY; Kamphuisen PW; Meyer G; Bauersachs R; Janas MS; Jarner MF; Khorana AA;
JAMA; 2015 Aug; 314(7):677-686. PubMed ID: 26284719
[TBL] [Abstract][Full Text] [Related]
13. Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months.
Schulman S; Lindmarker P; Holmström M; Lärfars G; Carlsson A; Nicol P; Svensson E; Ljungberg B; Viering S; Nordlander S; Leijd B; Jahed K; Hjorth M; Linder O; Beckman M
J Thromb Haemost; 2006 Apr; 4(4):734-42. PubMed ID: 16634738
[TBL] [Abstract][Full Text] [Related]
14. Patients with high levels of circulating endothelial progenitor cells (EPC) following at least three months of anticoagulation for unprovoked venous thromboembolism (VTE) are at low risk of recurrent VTE-Results from the ExACT randomised controlled trial.
Bradbury C; Buckley T; Sun YZ; Rose P; Fitzmaurice D
EClinicalMedicine; 2019 Dec; 17():100218. PubMed ID: 31891148
[TBL] [Abstract][Full Text] [Related]
15. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer.
Akl EA; Kahale L; Barba M; Neumann I; Labedi N; Terrenato I; Sperati F; Muti P; Schünemann H
Cochrane Database Syst Rev; 2014 Jul; (7):CD006650. PubMed ID: 25004410
[TBL] [Abstract][Full Text] [Related]
16. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients.
Prandoni P; Noventa F; Ghirarduzzi A; Pengo V; Bernardi E; Pesavento R; Iotti M; Tormene D; Simioni P; Pagnan A
Haematologica; 2007 Feb; 92(2):199-205. PubMed ID: 17296569
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
Coleman CI; Bunz TJ; Turpie AGG
Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
[TBL] [Abstract][Full Text] [Related]
18. Effect of testing for cancer on cancer- and venous thromboembolism (VTE)-related mortality and morbidity in people with unprovoked VTE.
Robertson L; Yeoh SE; Stansby G; Agarwal R
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD010837. PubMed ID: 28832905
[TBL] [Abstract][Full Text] [Related]
19. Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism.
Robertson L; Strachan J
Cochrane Database Syst Rev; 2017 Feb; 2(2):CD006771. PubMed ID: 28195640
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
